Evidence map›Paper›PMID 36499472›Full record

ArticleInternational journal of molecular sciences2022

Deletion of TNF in Winnie-

Giulio Verna, Marina Liso, Elisabetta Cavalcanti, Raffaele Armentano, Alessandro Miraglia, Vladia Monsurrò, Marcello Chieppa, Stefania De Santis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Giulio VernaDepartment of Pharmacy, University of Salerno, 84084 Fisciano, Italy.ORCID 0000-0001-8329-0370
Marina LisoNational Institute of Gastroenterology “S. de Bellis”, IRCCS Research Hospital, 70013 Castellana Grotte, Italy.ORCID 0000-0002-8766-1869
Elisabetta CavalcantiNational Institute of Gastroenterology “S. de Bellis”, IRCCS Research Hospital, 70013 Castellana Grotte, Italy.ORCID 0000-0003-2952-0053
Raffaele ArmentanoNational Institute of Gastroenterology “S. de Bellis”, IRCCS Research Hospital, 70013 Castellana Grotte, Italy.ORCID 0000-0003-1661-5504
Alessandro MiragliaDepartment of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy.ORCID 0000-0003-0874-4429
Vladia MonsurròDepartment of Medicine, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-9653-8432
Marcello Chieppa *Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy.
Stefania De Santis *Department of Pharmacy-Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy.ORCID 0000-0001-6877-2208
Gastroenterology Hospital "Saverio de Bellis" · ITUniversity of Salento · ITUniversity of Bari Aldo Moro · ITUniversity of Salerno · ITUniversity of Verona · IT

Funding

Italian Ministry of Health GR-2011-02347991University of Bari Aldo Moro AIM1801289 - attività 3 - linea 1
6 · The paper itself

Abstract

Colorectal cancer (CRC) is among the best examples for depicting the relationship between inflammation and cancer. The introduction of new therapeutics targeting inflammatory mediators showed a marked decrease in the overall risk of CRC, although their chemopreventive potential is still debated. Specifically, a monoclonal antibody that blocks tumor necrosis factor (TNF), infliximab, increases CRC risk in inflammatory bowel disease patients. To address the axis between TNF and CRC development and progression, we depleted the

Indexed as

ColitisColitis-Associated NeoplasmsColorectal NeoplasmsAnimalsDisease Models, AnimalDisease ProgressionInflammationMiceTumor Necrosis Factor-alphaTumor Necrosis Factor-alphaanimal modelscolon cancerinflammationTNFulcerative colitis

Identifiers

PMID36499472
PMCPMC9737576
OpenAlexW4311099031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.